Home › Research › Down syndrome and Alzheimer's
The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI): Ten Years of Progress in Understanding Alzheimer's in Down Syndrome
Laura Videla, Bessy Benejam, Isabel Barroeta, Susana Fernández, Javier Arranz, Íñigo Rodríguez‐Baz, José Enrique Arriola‐Infante, Lucía Maure‐Blesa et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The DABNI cohort included 1,135 participants with a mean age of 42.82 years (SD = 11.56), 46.3% of whom are female. At baseline, 673 participants were asymptomatic or cognitively stable, 113 had prodromal AD, 239 had AD dementia, and 110 were uncertain due to non-AD conditions. The cohort's intellectual disability level distribution was 20% mild, 50% moderate, 20% severe, and 7% profound. Over 10,000 visits have demonstrated that AD progression is rare before age 40, but high thereafter (57.5% of individuals over 50 progress within 5 years). Neuropsychological assessments and biomarkers have shown strong diagnostic performance for symptomatic AD, and a prolonged and predictable preclinical phase similar to autosomal dominant AD. The initiative is actively participating in three clinical trials and has yielded a robust body of work, with nearly 100 publications. Table 1 shows the number of clinical visits and biomarker studies in the whole sample and stratified by clinical diagnosis. In 10 years, the DABNI study has become one of the largest multimodal initiatives on AD in adults with DS and has provided critical insights into disease progression and biomarkers, advancing interventions and clinical research.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 1,135 participants. This ten-year study of over 1,100 people with Down syndrome found that Alzheimer's progression is rare before age 40 but common after 50, with a long predictable phase before symptoms. Reported effect size: 46.3%; 57.5%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Videla, L., Benejam, B., Barroeta, I., Fernández, S., Arranz, J., Rodríguez‐Baz, Í., et al. (2025). The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI): Ten Years of Progress in Understanding Alzheimer's in Down Syndrome. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_106426
Vancouver
Videla L, Benejam B, Barroeta I, Fernández S, Arranz J, Rodríguez‐Baz Í, et al. The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI): Ten Years of Progress in Understanding Alzheimer's in Down Syndrome. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_106426. PMID: 41518664.
BibTeX
@article{videla2025-41518664,
author = {Videla, Laura and Benejam, Bessy and Barroeta, Isabel and Fernández, Susana and Arranz, Javier and Rodríguez‐Baz, Íñigo and Arriola‐Infante, José Enrique and Maure‐Blesa, Lucía and others},
title = {{The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI): Ten Years of Progress in Understanding Alzheimer's in Down Syndrome}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_106426},
pmid = {41518664},
url = {https://doi.org/10.1002/alz70856_106426}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The DABNI cohort included 1,135 participants with a mean age of 42.82 years (SD = 11.56), 46.3% of whom are female.
- At baseline, 673 participants were asymptomatic or cognitively stable, 113 had prodromal AD, 239 had AD dementia, and 110 were uncertain due to non-AD conditions.
- The cohort's intellectual disability level distribution was 20% mild, 50% moderate, 20% severe, and 7% profound.
- Over 10,000 visits have demonstrated that AD progression is rare before age 40, but high thereafter (57.5% of individuals over 50 progress within 5 years).
- Neuropsychological assessments and biomarkers have shown strong diagnostic performance for symptomatic AD, and a prolonged and predictable preclinical phase similar to autosomal dominant AD.
Why it matters
This ten-year study of over 1,100 people with Down syndrome found that Alzheimer's progression is rare before age 40 but common after 50, with a long predictable phase before symptoms. The findings support using this population to study early Alzheimer's and to test interventions.
Study details
- Study designlongitudinal study
- Participants1,135
- Effect size46.3%; 57.5%
- Evidence strengthModerate
How this study scored 51/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,135 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Juan Fortea: h-index 72 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Universitat de Barcelona: institution h-index 1,049 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41518664) |
| Free to read | 2 / 2 | Free to read |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70856_106426
- PubMed: 41518664
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.